Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia

Leukemia

Volumn 11, Issue 7, 1997, Pages 933-939

  Hochhaus, A ^a,b   Yan, X H ^a   Willer, A ^b   Hehlmann, R ^b   Gordon, M Y ^a   Goldman, J M ^a   Melo, J V ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Interferon regulatory factors; Interferon

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD34 ANTIGEN; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS;

EID: 0030873359     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400723     Document Type: Article

References (24)

1. Tanaka N, Taniguchi T. Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the Interferon system. Adv Immunol 1992; 52: 263-281.
2. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989; 58: 729-739.
3. Sims SH, Cha Y, Romine MF, Gao PQ, Gottlieb K, Deisseroth AB. A novel inteferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol Cell Biol 1993; 13: 690-702.
4. Harada H, Takahashi EI, Itoh S, Harada K, Hori TA, Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol 1994; 14: 1500-1509.
5. Cha Y, Deisseroth AB. Human interferon regulatory factor 2 gene: intron-exon organization and functional analysis of 5′-flanking region. J Biol Chem 1994; 269: 5279-5287.
6. Abdollahi A, Lord KA, Hoffman-Liebermann B, Liebermann DA. Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin-6 and leukemia inhibitory factor: role in growth inhibition. Cell Growth Diff 1991; 2: 401-407.
7. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 971-974.
8. Sato T, Selleri C, Young NS, Maciejewski JP. Hematopoietic inhibition by interferon-γ is partially mediated through interferon regulatory factor-1. Blood 1995; 86: 3373-3380.
9. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia. Current status and investigational options. Blood 1996; 87: 3069-3081.
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gornez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
11. Kloke O, Niederle N, Qiu JY, Wandl U, Mortiz T, Nagel Hiemke M, Hawig I, Opalka B, Seeber S, Becher R. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993; 83: 399-403.
12. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronicphase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984.
13. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges F-L, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H and the German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukema. Blood 1994; 84: 4064-4077.
14. Kantarjian HM, Smith L, O'Brien S, Beran M, Pierce S, Talpaz M and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
15. Hasford J, Ansari H, Pfirrmann M, Hehlmann R and the German CML Study Group. Analysis and validation of prognostic factors for CML. Bone Marrow Transplant 1996; 17: (Suppl. 3): S49-S54.
16. Galvany D, Cawley C. Mechanism of action of α-interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol 1989; 73: 475-479.
17. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499-505.
18. Cross NCP, Melo JV, Feng L, Goldman JM. An optimised multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
19. Reiter A, Skladny H, Hochhaus A, Seifarth W, Heimpel H, Bartram CR, Cross NCP, Hehlmann R. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 1997; 97: 86-93.
20. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
22. Cross NCP. Detection of BCR-ABL by RT-PCR in haematological malignancies. In: Cotter FE (ed). Molecular Diagnosis of Cancer. Humana Press: New Jersey, 1996, pp 25-36.
23. Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NCP. Quantitative molecular methods to monitor the response of CML patients to interferon-α. Bone Marrow Transplant 1996; 17 (Suppl. 3): S41-S44.
24. Fischer T, Aman J, van der Kuip H, Rudolf G, Peschel C, Autlitzky WE, Huber C. Induction of Interferon regulatory factors, 2′-5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Br J Haematol 1996; 92: 595-603.